Section Arrow
CDTX.NASDAQ
- Cidara Therapeutics
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 21.58
+0.75 (+3.60%)
Day High 
21.925 
Prev. Close
20.83 
1-M High
25.7774 
Volume 
67.45K 
Bid
12.92
Ask
28
Day Low
19.83 
Open
20.55 
1-M Low
20.15 
Market Cap 
228.16M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 22.42 
20-SMA 22.82 
50-SMA 21.79 
52-W High 28.42 
52-W Low 10.004 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-26.75/-9.38
Enterprise Value
230.10M
Balance Sheet
Book Value Per Share
14.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.28M
Operating Revenue Per Share
5.16
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.